Cardiovascular

Displaying 1 - 10 of 24


pECHO: Easy to Use Smartphone App for Assisting in Transesophageal Echocardiography Exam

Transesophageal echocardiography (TEE) is a test that uses high-frequency sound waves to create images of the heart. It provides more detail that a standard echocardiogram. Vanderbilt researchers have created a software that creates an easy to follow, step-by-step procedure for a transesophageal echocardiography exam.


Licensing Contact

Masood Machingal

615.343.3548

Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Clarissa Muere

615.343.2430

Automated Inflatable Binder to Counter the Effects of Orthostatic Hypotension

Vanderbilt scientists have developed an automated inflatable abdominal binder that can detect when a patient moves from a prone or sitting positon to a standing position and automatically apply a sustained servo-controlled compression pressure in order to counter the effects of OH. The binder is as effective as conventional drug therapy in controlling OH, without subjecting patients to potentially harmful side effects and interactions with other medications.


Licensing Contact

Taylor Jordan

615.936.7505
Medical Devices
Cardiovascular

Targeting microRNAs as a Treatment for Vascular Disease

Vanderbilt researchers have identified a highly expressed microRNA crucial in angiotensin induced hypertension; and developed a therapeutic strategy that focuses on local or systemic administration of antisense microRNA to inhibit microRNA expression as treatment for vascular diseases. Promising data in animal models reveals that the inhibition of such microRNA not only prevents fibrosis but also reverses previously established aortic stiffening.


Licensing Contact

Jody Hankins

615.322.5907

Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Cardiovascular

Prostaglandin E Receptor-2 Null Mice

Prostaglandin E receptor-2 (EP2) null mice on a C57BL/6 background.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Animal Model
Cardiovascular

Luciferase Reporter System for Viral Detection in Vitro and in Vivo

This research targets Respiratory Syncytial Virus.


Licensing Contact

Taylor Jordan

615.936.7505

Rabbit Anti-human Large Neutral Amino Acid Transporter Antibody

This research targets LAT-1.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Roy Zent
Research Tools
Antibody

Anti-Armadillo Repeat Gene Deleted in Velo-cardiofacial Syndrome Monoclonal Antibody

This research targets ARVCF.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Albert Reynolds
Research Tools
Antibody

Endothieal Nitric Oxide Synthase Null Mice (db/db background)

This research targets eNOS.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Raymond Harris
Research Tools
Animal Model
Cardiovascular